Chemours (NYSE:CC) Issues Earnings Results, Misses Estimates By $0.05 EPS

Chemours (NYSE:CC) issued its quarterly earnings data on Monday. The specialty chemicals company reported $0.21 earnings per share for the quarter, missing the consensus estimate of $0.26 by ($0.05), FiscalAI reports. The business had revenue of $1.54 billion for the quarter, compared to the consensus estimate of $1.53 billion. Chemours had a negative net margin of 5.00% and a positive return on equity of 60.64%. Chemours’s revenue was up 3.0% compared to the same quarter last year. During the same period in the previous year, the business posted $0.40 EPS.

Chemours Stock Performance

NYSE:CC traded down $0.33 during midday trading on Monday, reaching $13.20. The stock had a trading volume of 4,477,364 shares, compared to its average volume of 2,810,770. Chemours has a 1-year low of $10.44 and a 1-year high of $28.67. The firm’s fifty day simple moving average is $14.22 and its 200-day simple moving average is $18.27. The company has a debt-to-equity ratio of 18.98, a current ratio of 1.66 and a quick ratio of 0.88. The stock has a market capitalization of $1.99 billion, a P/E ratio of -6.91 and a beta of 1.41.

Chemours Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 15th. Investors of record on Monday, November 16th will be issued a dividend of $0.0875 per share. This represents a $0.35 annualized dividend and a dividend yield of 2.7%. The ex-dividend date of this dividend is Monday, November 16th. Chemours’s dividend payout ratio is currently -18.32%.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on CC shares. Morgan Stanley set a $18.00 price target on shares of Chemours in a research note on Monday, August 10th. Truist Financial reduced their price objective on shares of Chemours from $24.00 to $20.00 and set a “buy” rating for the company in a research note on Tuesday, October 20th. Mizuho cut shares of Chemours from an “outperform” rating to a “neutral” rating and decreased their price objective for the stock from $18.00 to $15.00 in a report on Wednesday, October 14th. Barclays initiated coverage on shares of Chemours in a research report on Monday, October 12th. They set an “equal weight” rating and a $16.00 target price on the stock. Finally, Weiss Ratings downgraded shares of Chemours from a “sell (d)” rating to a “sell (d-)” rating in a research report on Thursday, August 6th. Three investment analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Chemours currently has a consensus rating of “Hold” and an average price target of $17.73.

Key Headlines Impacting Chemours

Here are the key news stories impacting Chemours this week:

• Positive Sentiment: Chemours launched its Faizeon™ two-phase liquid-cooling portfolio for AI, high-performance-computing and high-density data centers. The products are designed to manage rising heat loads while reducing energy and water consumption, offering a potential growth opportunity in data-center infrastructure. Chemours Launches Faizeon Two-Phase Liquid Cooling Solutions for AI Data Centers
• Neutral Sentiment: Third-quarter revenue of $1.54 billion slightly exceeded the $1.53 billion analyst consensus, suggesting demand was broadly in line with expectations. However, additional operating metrics highlighted by analysts may provide a more mixed view of segment performance. Here’s What Key Metrics Tell Us About Chemours Q3 Earnings
• Negative Sentiment: Chemours reported third-quarter adjusted EPS of $0.21, below the $0.27 consensus and down from $0.40 a year earlier. The company also posted a negative 5% net margin, reinforcing concerns about profitability and the earnings outlook. The Chemours Company Reports Third Quarter Results
• Negative Sentiment: Multiple law firms announced or promoted a securities class action alleging that Chemours made misleading statements between February 20 and August 4, 2026, particularly concerning Opteon aftermarket demand and the subsequent guidance cut. The lead-plaintiff deadline is December 7, 2026. Reports that UBS, Morgan Stanley and JPMorgan reduced price targets add to the negative sentiment. CC Shareholder Alert

Insiders Place Their Bets

In other Chemours news, CEO Denise Dignam acquired 3,378 shares of the company’s stock in a transaction dated Tuesday, August 11th. The shares were acquired at an average cost of $14.95 per share, for a total transaction of $50,501.10. Following the completion of the purchase, the chief executive officer owned 339,916 shares of the company’s stock, valued at approximately $5,081,744.20. This trade represents a 1.00% increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CFO Shane Hostetter bought 3,350 shares of the firm’s stock in a transaction that occurred on Thursday, August 6th. The shares were acquired at an average price of $14.94 per share, with a total value of $50,049.00. Following the purchase, the chief financial officer owned 102,698 shares in the company, valued at $1,534,308.12. This trade represents a 3.37% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders bought a total of 8,663 shares of company stock valued at $130,601 in the last quarter. Insiders own 0.85% of the company’s stock.

About Chemours

The Chemours Company (NYSE: CC) is a global chemistry company that develops and manufactures performance chemicals and advanced materials for industrial and consumer applications. The company serves customers in markets including automotive, construction, energy, electronics, healthcare, and general manufacturing.

Chemours operates through businesses focused on Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. Its products include titanium dioxide pigments used to provide whiteness and opacity in coatings, plastics, and paper; refrigerants and related thermal-management solutions; and high-performance fluoropolymers and specialty materials sold under brands such as Teflon™, Viton™, and Nafion™.

Headquartered in Wilmington, Delaware, Chemours serves customers globally through manufacturing facilities, research and development operations, and commercial activities across North America, Latin America, Europe, and Asia-Pacific.